Four independent studies show rovalpituzumab tesirine ineffective against small cell lung cancer
Four independent studies demonstrate that rovalpituzumab tesirine for small-cell lung cancer (SCLC) is not effective against SCLC, casting a pall over the future of the therapy and closing a door that seemed opened four years ago when the first study on the therapy was published.
Read Original Article: Four independent studies show rovalpituzumab tesirine ineffective against small cell lung cancer »
